Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

IMU Biosciences

Request full access

AI immune-profiling platform CytAtlas for precision medicine

London, United KingdomFounded 2019Biotech & Life Sciences

About IMU Biosciences

IMU Biosciences is a UK biotechnology company founded in 2021 by Dr Adam Laing, Dr Tom Hayday and Mario Cantero that builds CytAtlas, an AI-powered systems immune-profiling platform rooted in research from King’s College London and the Francis Crick Institute. From a small blood sample CytAtlas analyses vast immune datasets to quantify thousands of cell subsets for applications in immuno-oncology, cell therapy, autoimmune disease and transplantation, and IMU participates in the UK MANIFEST cancer-immunotherapy consortium. After an earlier £11.5 million Series A tranche in January 2024 led by Molten Ventures, in June 2026 IMU announced an oversubscribed financing that brought its Series A to over $53 million (about £40 million), co-led by IQ Capital and Molten Ventures with the British Business Bank, Meltwind and existing investors, taking total funding to about $60 million to expand operations, clinical-platform infrastructure and programs in transplantation and cancer immunotherapy. Sources: company/British Business Bank Jun 2026; Fierce Biotech; BioXconomy.

Source: Dealroom company data

At a glance

Status
Operational
Employees
77
Open positions
2
Dealroom signal
81.1/100
Industry
Health
Sub-industry
BioTechnology, Health Platform
Sector
Biotechnology, uk rio, Core AI, Precision Medicine, UKis Digital and technologies, uk is8 digital and technologies, uk is8 life sciences, Cell Therapy, Hard Tech, Woman Founder
Business model
SaaS

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Jun 2026 $53M $211M British Business Bank · Meltwind · Molten Ventures · IQ Capital ↗
SERIES AOther financing Jan 2024 $15M $61M Molten Ventures ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

IMU Biosciences website traffic

Latest recorded traffic for IMU Biosciences is 5.7K monthly website visits, up 119.2% over the last three months. IMU Biosciences's team grew 11.6% over the past year.

Latest monthly visits5.7K 3-month web change+119.2% 1-year team growth+11.6%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

IMU Biosciences in the London ecosystem

Live from Dealroom

The IMU Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Beaumont Capital

Series A4 investors entered at this stage

  • Molten Ventures
  • IQ Capital
  • British Business Bank
  • Meltwind
Team profiled 13 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See IMU Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.